India has volunteered to participate in
the World Health Organization’s (WHO) ongoing solidarity trial for
developing vaccines for Covid-19.
Background
WHO with its partners is organizing a study
called the solidarity trial in many countries in which some of the untested
treatments are compared with each other. The study has been designed to
generate the robust data needed to show which treatments are the most
effective.
Details
Ø In order to look at newer drugs that might
come, India is soon likely to participate in the WHO solidarity trial for
COVID-19. Earlier we did not do it because our numbers were so small and
contribution would have looked minuscule.
Ø WHO’s multi-country solidarity
trials aims to isolate drugs approved by regulators for other diseases
that can be utilised in the Covid-19 fight. The reason already safety-tested
drugs are being looked at is because these do not need lengthy clinical trials.
Ø Among the drugs lined up for immediate
testing are antiviral intravenous drug remdesivir, HIV combination lopinavir
and ritonavir sold as Kaletra; and anti-malarial chloroquine, and a related
drug, hydroxychloroquine.
Ø Many countries, including Argentina, Bahrain,
Canada, France, Iran, Norway, South Africa, Spain, Switzerland, and Thailand,
have already confirmed that they will join the solidarity trial, according to
WHO.
Ø WHO has also created a Covid-19 Solidarity
Response Fund, to help provide protective equipment for front-line health
workers, equip diagnostic laboratories, improve surveillance and data
collection, establish and maintain intensive care units.
Ø It also aims to strengthen supply chains,
accelerate research and development of vaccines and therapeutics, and take
other critical steps to scale up the public health response to the Covid-19
pandemic.
Comments
Post a Comment